Evidence map›Paper›PMID 41849419›Full record

ArticlePloS one2026

Preparation and application of Taq DNA polymerase monoclonal antibody guided by structural domain analysis.

Xiaoqian Zhu, Tingting Zhang, Haiyu Zhao, Bingbing Hou, Mingyue Fu, Qianshan Zhao, Tong Xu, Jixiang Zhao, Jiming Xie, Yuyao Zhou and 2 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaoqian ZhuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.ORCID https://orcid.org/0009-0008-3322-535X
Tingting ZhangShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Haiyu ZhaoShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Bingbing HouShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Mingyue FuShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Qianshan ZhaoShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Tong XuShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Jixiang ZhaoShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Jiming XieShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Yuyao ZhouShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.
Suxia LiState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.ORCID https://orcid.org/0009-0003-3939-6436
Peng WangShanghai Yaxin Biotechnology Co., Ltd., Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hot-start polymerase chain reaction (hot-start PCR) effectively inhibits non-specific product amplification during PCR, with hot-start Taq DNA polymerase (HS Taq) serving as the critical component. Current HS Taq preparation methods, including chemical modification and aptamer-based approaches, exhibit limitations such as prolonged activation time, reduced enzyme activity, and inadequate blocking specificity. In contrast, antibody-mediated hot-start Taq offers distinct advantages: rapid activation, stable enzymatic performance, and high blocking specificity through targeted binding to functional domains. While antibody-based hot-start Taq DNA polymerases are widely utilized for their high efficiency and specificity, their development often relies on commercial sources or complex genetic engineering. This dependency constrains the independent and customizable development of core PCR components. To address this, our study established a streamlined platform for generating highly effective monoclonal antibodies that inhibit Taq enzyme activity. The key innovation lies in our structure-guided, domain-specific immunization strategy: instead of using the full-length enzyme, we targeted the polymerase domain (Taq-P) to generate a specific monoclonal antibody that acts as a reversible inhibitor. This approach overcomes the major challenge of generating functional antibodies against cryptic epitopes, which are poorly immunogenic in the full-length protein. This antibody sterically blocks the enzyme's active site at room temperature, preventing non-specific priming during PCR setup, and dissociates upon thermal activation to restore full activity. The resulting hot-start Taq enzyme significantly reduced non-specific amplification in quantitative PCR assays, and its practical utility was successfully demonstrated in detecting fungal pathogens and respiratory viruses using clinical samples. This study provides a feasible and effective strategy for the autonomous development of critical reagents for molecular diagnostics.

Indexed as

Antibodies, MonoclonalTaq PolymeraseAnimalsMicePolymerase Chain ReactionProtein DomainsAntibodies, MonoclonalTaq Polymerase

Identifiers

PMID41849419
PMCPMC12998814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.